Arkolith/Insider Trading/TRIL/Form 4

Uger Robert

Chief Scientific OfficerTrillium Therapeutics Inc. (TRIL) · full profile →Form 4 · filed Jun 9, 2021
Net Selling
Open-Market Buys
$0
Open-Market Sells
$30K
Net Open-Market Flow
-$30K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 7, 2021Option exercise(M)4K$0.32$1K4K
Jun 7, 2021Sell(S)4K$8.27$30K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 7, 2021Option exercise(M)4K—$0106K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-21-005487) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML